Spravato for Bipolar: What to Expect Before, During, and After Treatment
Bipolar disorder and depression share surface-level similarities but are clinically distinct conditions - and that distinction has real consequences when it comes to treatment decisions.
For patients with bipolar disorder who experience depressive episodes that have not responded to standard medications, the question of whether esketamine is a viable option has become increasingly relevant.
Spravato for bipolar is a subject that generates genuine clinical interest and, at the same time, requires careful qualification. The approved indications, the specific risks involved in bipolar presentations, and the practical realities of treatment are all worth understanding before any decision is made.
What Spravato Is Approved For - and Where Bipolar Fits
Spravato received FDA approval in 2019 for treatment-resistant depression in adults and for major depressive disorder with acute suicidal ideation or behavior. Both indications specify unipolar major depressive disorder. Bipolar disorder - including bipolar I and bipolar II - is not part of those approved indications.
That gap is not arbitrary. The clinical trials that supported FDA approval specifically enrolled patients with unipolar treatment-resistant depression. Patients with a bipolar diagnosis were largely excluded, which means the formal evidence base for spravato bipolar disorder use is limited compared to what exists for unipolar presentations.
When a psychiatrist considers Spravato for a patient with bipolar disorder, they are working off-label. Most of the clinical familiarity with esketamine has been built through spravato treatment for depression in unipolar presentations, which means the experience base for bipolar cases is narrower and the clinical footing less established.
This is legal, not unusual in psychiatric practice, and in some cases clinically defensible - but it comes with different implications for insurance coverage, available clinical guidance, and the degree of certainty a clinician can offer about outcomes.
Why Bipolar Depression Is Particularly Complex
Treating depression in bipolar disorder is more complicated than treating unipolar depression. Antidepressants that work well in unipolar presentations can destabilize patients with bipolar disorder - triggering manic or hypomanic episodes, accelerating mood cycling, or producing mixed states.
This is one reason psychiatrists approach any new treatment for bipolar depression with added caution, and spravato for bipolar disorder is no exception to that clinical logic.
The theoretical concern with esketamine is similar: a treatment that rapidly shifts mood in a depressive direction could, in susceptible individuals, overshoot into mood elevation. Whether this risk is clinically significant with esketamine specifically has not been studied in large controlled trials focused on bipolar populations.
Before Treatment: Assessment and Preparation
For patients with bipolar disorder who are being considered for spravato treatment for bipolar depression, the pre-treatment evaluation is more detailed than it would be for a straightforward unipolar case. Psychiatrists typically assess several factors before proceeding:
Current mood stability and whether the patient is in a depressive phase, a mixed state, or approaching a hypomanic baseline
Medication regimen, particularly whether a mood stabilizer is in place - esketamine would typically not be considered without adequate mood stabilization already established
History of manic or hypomanic episodes triggered by antidepressant medications, which may indicate higher risk of mood switching
Patients should come to these conversations prepared to give a thorough account of their mood history, including any past episodes of mania, hypomania, or rapid cycling. This information directly affects how a psychiatrist weighs the risk-benefit calculation for esketamine.
Practically speaking, patients should also prepare for the logistical demands of treatment. Each session takes place at a REMS-certified clinical facility. Driving on the day of treatment is not permitted, which means arranging transportation needs to be planned in advance. The initial phase requires twice-weekly sessions, so schedule availability matters from the outset.
During Treatment: What the Experience Involves
The administration process for spravato for bipolar disorder follows the same protocol used in approved-indication cases. There is no modified bipolar-specific procedure - the session structure, monitoring requirements, and post-dose observation period are consistent across all patients.
Session Structure and Immediate Effects
Spravato is a self-administered nasal spray used under direct clinical supervision. Patients remain at the facility for a minimum of two hours following each dose while staff monitors for adverse effects.
The dosing schedule typically begins with twice-weekly sessions for the first four weeks, followed by once-weekly sessions through weeks five to eight, and then a maintenance phase every 1 to 2 weeks.
During the session itself, dissociative effects are common and expected. These include:
Perceptual changes, a sense of detachment from surroundings, or altered sense of time
Dizziness, nausea, and temporary blood pressure increases
Sedation that persists for several hours after the session ends
For patients with bipolar disorder, clinical staff also monitor for any signs of mood elevation during or after sessions. While dissociation and sedation are the primary expected effects, mood monitoring takes on added significance in this population given the theoretical risk of mood switching.
Mood Monitoring During the Treatment Course
Psychiatrists managing spravato bipolar disorder cases typically implement more frequent mood check-ins than they would for unipolar patients. This might involve standardized mood rating scales administered before each session, regular contact between sessions, and clear guidance to patients and caregivers about what signs of mood elevation to watch for and report.
This kind of active monitoring is not a reason to avoid treatment if the clinical case supports it - but it is a realistic feature of what responsible spravato treatment for bipolar disorder looks like in practice.
After Treatment: Maintenance, Monitoring, and Managing Expectations
The post-acute phase of spravato for bipolar treatment raises questions that are somewhat different from those in unipolar depression. How long to continue, how to assess response, and how to integrate esketamine with existing mood stabilizers all require ongoing clinical judgment.
Response to treatment varies. Some patients experience meaningful reduction in depressive symptoms within the first few sessions.
Others see more gradual improvement, and some do not respond sufficiently to justify continued use. In a bipolar context, the definition of a good response includes not only reduced depression scores but also the absence of mood destabilization.
Key considerations during the maintenance phase include:
Whether the mood stabilizer regimen needs adjustment based on how the patient responds to esketamine
How to define the endpoint for treatment - continued maintenance sessions are resource-intensive and need to be justified by ongoing clinical benefit
What to do if depressive symptoms return after a period of improvement, including whether re-induction or increased session frequency is appropriate
Patients and families should maintain open communication with the treating psychiatrist throughout this phase. Any changes in sleep patterns, energy levels, irritability, or goal-directed behavior - all of which can be early signs of mood elevation - warrant prompt clinical contact rather than a wait-and-see approach.
Realistic Expectations for Patients and Families
Spravato for bipolar disorder is not a straightforward or universally recommended treatment path. The absence of bipolar-specific trial data, the real risks associated with mood switching, and the logistical demands of the treatment schedule all need to be weighed against the potential benefit for a patient who has not found adequate relief through other approaches.
That said, for patients with well-stabilized bipolar disorder and a significant history of treatment-resistant depressive episodes, the clinical conversation around esketamine is a legitimate one.
The key is that it happens with a psychiatrist who has experience managing both bipolar disorder and esketamine treatment - not as a shortcut to quick relief, but as a carefully considered option within a broader care plan.
Spravato for bipolar remains an area where clinical practice is ahead of the formal evidence base. Patients deserve to know that, and they deserve to make decisions with that context clearly in view.